Maximilian J Hochmair1, Alessandro Morabito2, Desiree Hao3, Cheng-Ta Yang4, Ross A Soo5, James C-H Yang6, Rasim Gucalp7, Balazs Halmos7, Lara Wang8, Angela Märten9, Tanja Cufer10. 1. Department of Respiratory & Critical Care Medicine, & Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, Sanatoriumstrasse 2, Vienna 1140, Austria. 2. Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale'-IRCCS, 80131 Napoli, Italy. 3. Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada. 4. Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 5. Department of Haematology-Oncology, National University Hospital, Singapore. 6. Department of Oncology, National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei, Taiwan. 7. Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA. 8. Boehringer Ingelheim Taiwan Ltd, Taiwan. 9. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 10. University Clinic Golnik, University of Ljubljana, Ljubljana, Slovenia.
Abstract
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT03370770.
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT03370770.
Authors: Wang Chun Kwok; James Chung Man Ho; Terence Chi Chun Tam; Mary Sau Man Ip; David Chi Leung Lam Journal: Thorac Cancer Date: 2022-06-06 Impact factor: 3.223